KalVista Pharmaceuticals (KALV) Amortizatization of Intangibles (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Amortizatization of Intangibles of -$7000.0 for Q3 2025, down 240.0% on a YoY basis from $5000.0 in Q3 2024, and down 333.33% sequentially from $3000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Amortizatization of Intangibles (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 10 years of Amortizatization of Intangibles data on file, last reported at -$7000.0 in Q3 2025.
- For the quarter ending Q3 2025, Amortizatization of Intangibles fell 240.0% year-over-year to -$7000.0; the trailing twelve-month figure through Jul 2025 stood at $6000.0 (down 82.86% YoY), and the FY2025 full-year result was $14000.0, down 84.78% from the prior year.
- Amortizatization of Intangibles eased to -$7000.0 in Q3 2025, from $3000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $753000.0 in Q3 2021 to a low of -$7000.0 in Q3 2025.
- A 5-year average of $233277.8 and a median of $104000.0 in 2021 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 1007.35% in 2021 and slumped 240.0% in 2025, its largest moves.
- Tracing KALV's Amortizatization of Intangibles over 5 years: stood at $671000.0 in 2021, then tumbled by 57.23% to $287000.0 in 2022, then slumped by 92.68% to $21000.0 in 2023, then plunged by 76.19% to $5000.0 in 2024, then tumbled by 240.0% to -$7000.0 in 2025.
- Business Quant data shows KALV's Amortizatization of Intangibles at -$7000.0 in Q3 2025, $3000.0 in Q2 2025, and $5000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -7,000.00 |
| Jul 31, 2025 | -7,000.00 |
| Apr 30, 2025 | 3,000.00 |
| Apr 30, 2025 | 3,000.00 |
| Oct 31, 2024 | 5,000.00 |
| Oct 31, 2024 | 5,000.00 |
| Jul 31, 2024 | 5,000.00 |
| Jul 31, 2024 | 5,000.00 |
| Apr 30, 2024 | 4,000.00 |
| Apr 30, 2024 | 4,000.00 |
| Jan 31, 2024 | 5,000.00 |
| Jan 31, 2024 | 5,000.00 |
| Oct 31, 2023 | 21,000.00 |
| Oct 31, 2023 | 21,000.00 |
| Jul 31, 2023 | 62,000.00 |
| Jul 31, 2023 | 62,000.00 |
| Apr 30, 2023 | 98,000.00 |
| Apr 30, 2023 | 98,000.00 |
| Jan 31, 2023 | 212,000.00 |
| Jan 31, 2023 | 212,000.00 |